Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Sponsor

Rhizen Pharmaceuticals SA (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05239910

Collaborator

(none)

Enrollment

Location

Arms

51.9

Anticipated Duration (Months)

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a phase II open label, two-arm parallel design study of T-CHOP in patients with treatment naïve PTCL. Two doses of tenalisib (400 mg BID and 800 mg BID) will be evaluated in separate groups (Group 1: 400 mg BID and Group 2: 800mg BID) when given with standard regimen of CHOP, followed by single agent maintenance treatment with tenalisib for 1 year. Recruitment of 20 patients each will be done in both groups in parallel.

All eligible patients will start with a run-in period, in which single agent tenalisib will be administered for 3 cycles of 21 days each. Post run-in period, all patients will proceed to receive tenalisib and CHOP regimen for next 6 cycles. After completion of 6 cycles of T-CHOP treatment, maintenance therapy with tenalisib will be initiated in patients showing CR and PR. These patients will continue to receive single agent tenalisib for 1 year.

Condition or Disease	Intervention/Treatment	Phase
Peripheral T Cell Lymphoma	Drug: Tenalisib	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

40 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open Label, Phase II Study to Evaluate the Efficacy and Safety of Tenalisib (RP6530), Given With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) Therapy for Front Line Treatment in Patients With Peripheral T-cell Lymphoma

Anticipated Study Start Date :

Jan 1, 2023

Anticipated Primary Completion Date :

Dec 1, 2026

Anticipated Study Completion Date :

May 1, 2027

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Tenalisib 400 mg BID and CHOP	Drug: Tenalisib Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.
Experimental: Tenalisib 800 mg BID and CHOP	Drug: Tenalisib Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.

Arm

Intervention/Treatment

Experimental: Tenalisib 400 mg BID and CHOP

Drug: Tenalisib

Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.

Experimental: Tenalisib 800 mg BID and CHOP

Drug: Tenalisib

Outcome Measures

Primary Outcome Measures

Complete Response (CR) rate at the end of T-CHOP treatment. [9 months]
CR rate is defined as the percentage of patients showing complete response as assessed by the Investigator according to the Lugano Classification.

Secondary Outcome Measures

Overall Response Rate (ORR) at the end of T-CHOP treatment. [9 months]
ORR is defined as sum of CR and PR rates, as assessed by the Investigator according to the Lugano Classification
Duration of Response (DoR), [3 years]
The duration of response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented.
Progression-Free Survival (PFS) [3 years]
PFS is defined as the duration of time from start of treatment to time of documentation of progression or death from any cause
Overall Survival (OS) [3 years]
OS is defined as the duration of time from start of treatment to death from any cause.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Provision of full informed consent prior to any study-specific procedures.
Pathologically confirmed diagnosis of PTCL according to WHO 2016 classification criteria EXCEPT following subtypes:

ALK-positive anaplastic T-cell lymphoma; CD30+ PTCL (who are eligible for BV and CHOP combination); extra-nodal NK/T-cell lymphoma, nasal type; HTLV1- associated lymphoma; primary cutaneous anaplastic T-cell lymphoma, T-cell lymphoma with only skin involvement

Disease status is defined as treatment naïve patients with PTCL who have not received prior systemic therapy for lymphoma.
Must have ECOG performance status ≤ 2
Patients must have measurable disease defined as at least one bi-dimensional measurable lesion assessed radiologically with a minimum measurement of > 1.5 cm in the longest diameter.
Patients must be fit to receive full-dose CHOP Therapy.
Adequate bone marrow, liver and renal functions

Exclusion Criteria:

Patients who have received prior systemic therapy for lymphoma or are receiving anticancer therapy including any investigational therapy (e.g., chemotherapy, biologic therapy, hormonal therapy).
Patients with known Central Nervous System (CNS) lymphoma or CNS involvement by lymphoma.
Active uncontrolled systemic fungal, bacterial or viral infection
Patient with ongoing or significant cardiac disease in last 6 months which according to the investigator can impact study participation
Patients with co-morbidities/complications
Known history of severe liver injury/disease
Active viral infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. and history of severe cutaneous reactions
Patient with any other active malignancy at the time of screening except for adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin,
Hypersensitivity to the active substance or to any of the excipients.
Pregnancy or lactation.
Concurrent medications or substance, the example of these treatment includes strong inhibitors or inducer of CYP3A4 enzyme or substrate of CYP3A4 with narrow therapeutic index.